Uncategorized
Glaukos Corporation Announces Completion of Patient Enrollment in U.S. Pivotal Clinical Trial for iStent inject®
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced the completion of patient enrollment in its U.S. Food and Drug Administration (FDA) pivotal Investigational Device Exemption (IDE) trial for the iStent inject® Trabecular Micro-Bypass Stent. The iStent inject relies on a similar fl
